Back to top

Analyst Blog

Zacks Equity Research

Bayer/Onyx Announce Cancer Data

BAYRY

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Bayer HealthCare, a unit of Bayer (BAYRY - Analyst Report) and partner Onyx Pharmaceuticals, Inc. recently announced data from a pivotal phase III study (CORRECT: n=760) of  oncology candidate, regorafenib (BAY 73-4506). The study evaluated patients suffering from metastatic colorectal cancer (mCRC) whose disease had progressed even after treatments with the standard drugs for the disease.

The multicenter, randomized, double-blind, placebo-controlled study was conducted in North America, Europe, China, Japan and Australia. We note that the pivotal study was unveiled in late 2011 following the recommendation of an independent data monitoring committee to allow patients in the placebo arm to be treated with regorafenib.

Data from the study revealed that mCRC patients treated with regorafenib plus the best supportive care lived approximately six weeks (median overall survival of 6.4 months) longer than those treated with placebo and the best supportive care (median overall survival of 5 months), thereby improving overall survival by 29% and meeting the primary endpoint of the study. Moreover, regorafenib treatment also resulted in a significant improvement in progression-free survival.

However, the difference in objective response rate between the two cohorts was statistically insignificant. Furthermore, treatment with regorafenib resulted in adverse events such as fatigue, hand-foot skin reaction, diarrhea, anorexia, voice changes, hypertension, oral mucositis apart from rash/desquamation.

Bayer intends to seek approval for the candidate in the mCRC indication in 2012. If regorafenib hits the market then Bayer has to make royalty payments to the tune of 20% on global sales of the candidate to Onyx, per the agreement inked last year. (Please refer to Onyx and Bayer Bury the Hatchet for details).

Our Recommendation

Currently, we have a Neutral stance on Bayer in the long run. The company carries a Zacks #4 Rank (Sell rating) in the short run. We have a similar long-term stance on Onyx. However, Onyx’s shares carry a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%